pulmonari tuberculosi develop drug treatment guidanc industri draft guidanc guidanc document distribut comment purpos comment suggest regard draft document submit within 60 day public feder regist notic announc avail draft guidanc submit electron comment httpswwwregulationsgov submit written comment docket manag staff hfa 305 food drug administr 5630 fisher lane rm 1061 rockvil md 20852 comment identifi docket number list notic avail publish feder regist question regard draft document contact ramya gopinath ramyagopinathfdahhsgov us depart health human servic food drug administr center drug evalu research cder decemb 20 22 clinic antimicrobi revis 1 pulmonari tuberculosi develop drug treatment guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 8555433784 301 7963400 fax 3014316353 email druginfofdahhsgov httpswwwfdagovdrugsguidancecomplianceregulatoryinformationguidancesdrug us depart health human servic food drug administr center drug evalu research cder decemb 20 22 clinic antimicrobi revis 1 contain nonbind recommend draft implement tabl content introduct 1 ii background 2 iii develop program 2 gener consider 2 1 earli phase clinic develop consider 2 eba 3 b phase 2 evalu 3 2 efficaci consider 3 3 safeti consider 3 b specif efficaci trial consider 4 1 trial design 4 2 trial popul 5 3 inclus exclus criteria 6 4 random stratif blind 7 5 specif popul 7 pediatr popul 7 b pregnant femal 8 c specif popul 9 6 dose select 9 7 choic compar 9 8 efficaci endpoint 9 9 trial procedur time assess 11 entri visit 11 b visit therapi therapi complet 12 10 statist consider 12 11 acceler approv consider 13 c consider 13 1 microbiolog consider 13 vitro studi 13 b vivo anim model 14 c drug resist crossresist 14 type cultur media identifi tuberculosi 15 e differenti relaps reinfect new infect 15 2 relev nonclin safeti consider 15 3 pkpd consider 16 phase 1phase 2 pk trial 16 b drug interact 16 c exposur respons 17 vitro hollow fibe r system model 17 4 foreign clinic data 17 5 data standard tb 17 6 label consider 18 refer 19 appendix 21 contain nonbind recommend draft implement 1 pulmonari tuberculosi 1 develop drug treatment 2 guidanc industry1 3 4 5 6 draft guidanc final repres current think food drug 7 administr fda agenc topic establish right person 8 bind fda public use altern approach satisfi requir 9 applic statut regul discuss altern approach contact fda staff respons 10 guidanc list titl page 11 12 13 14 introduct 15 16 purpos guidanc assist sponsor clinic develop investig 17 drug treatment pulmonari tuberculosi tb section 505 feder food 18 drug cosmet act fdc act 21 usc 355 fda regul 21 cfr part 312 19 part 601 2 specif guidanc provid fda current recommend 20 regard overal develop program new investig drug drug use 21 combin approv drug new treatment regimen includ one 22 investig drug support indic treatment pulmonari tb guidanc 23 address develop drug latent tb infect extrapulmonari tb 24 25 sponsor also refer guidanc industri codevelop two new 26 investig drug use combin june 2013 3 sponsor encourag discuss 27 fda program pathway facilit drug develop ight applic 28 develop program4 29 30 guidanc revis replac draft guidanc industri name issu 31 novemb 2013 revis includ detail regard nonclin model earli phase 32 studi trial design consider includ demonstr efficaci use superior 33 noninferior ni trial design addit updat made regard inclus 34 pediatr subject trial endpoint safeti consider label appendix 35 contain ni margin justif also updat 36 1 guidanc prepar divis anti infect center drug evalu research food drug administr 2 purpos guidanc refer drug includ human drug therapeut biolog product unless otherwis specifi 3 updat guidanc period make sure recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document 4 see guidanc industri expedit program seriou condit drug biolog may 2014 contain nonbind recommend draft implement 2 37 guidanc contain discuss gener issu statist analysi clinic 38 trial design topic address intern council harmonis ich 39 guidanc industri e9 statist principl clinic trial septemb 1998 e10 40 choic control group relat issu clinic trial may 2001 ich e10 41 respect 42 43 gener fda guidanc document establish legal enforc respons 44 instead guidanc describ agenc current think topic view 45 recommend unless specif regulatori statutori requir cite use 46 word sho uld agenc guidanc mean someth suggest recommend 47 requir 48 49 50 ii background 51 52 infect caus mycobacterium tuberculosi tuberculosi diagnos unit 53 state endem mani part world resist multipl drug coinfect 54 human immunodefici viru hiv pose challeng manag tb drug 55 new mechan action impr ove safeti profil fewer drug drug interact 56 treatment shorten combin regimen need manag tb 57 58 59 iii develop program 60 61 gener consider 62 63 1 earli phase clinic develop consider 64 65 nonclin evalu provid valuabl inform develop investig 66 drug see section iiic1 microbiolog consider section iiic2 relev nonclin 67 safeti consider section iiic3 pkpd consider 68 69 activ antimycobacteri drug evalu trial earli bactericid activ eba 70 andor phase 2 trial evalu microbiolog al outcom earli ime point 71 combin regimen sponsor evalu contribut drug treatment 72 effect 5 evalu phase 2 clinic develop nonclin studi see 73 section iiic1 microbiolog consider treatment pulmonari tb includ 74 one drug treatment regimen sponsor may develop one investig 75 drug part new combin regimen sponsor consult agenc earli 76 develop regard plan demonstr contribut investig drug 77 part combin regimen 78 79 5 recommend guidanc relev demonstr contribut individu new investig drug effect combin regimen consist requir 21 cfr 30050 fixedcombin prescriptio n drug human contain nonbind recommend draft implement 3 eba 80 81 applic investig drug studi eba trial evalu quantit 82 count viabl tuberculosi daili collect sputum provid inform 83 bactericid activ antimycobacteri drug trial intend evalu 84 antimycobacteri activ investig drug alon combin brief time 85 cours eg 7 14 day eba trial provid preliminari evid contribut 86 drug treatment effect combin regi men appropri subject 87 enrol eba trial includ immunocompet subject treatment nave adul subject 88 low risk infect ion drug resist tb subject evid extra pulmonari 89 diseas begin standard ofcar treatment pulmonari tb complet 90 eba trial 91 92 b phase 2 evalu 93 94 sponsor conduct phase 2 trial assess antimycobacteri activ n 95 investig drug regimen addit feasibl phase 2 develop program 96 includ dose rang studi studi assist determin appropri dose 97 regimen taken phase 3 phase 2 exploratori endpoint includ limit 98 follow 1 8 week evalu absenc acid fast bacilli afb sputum 2 99 time sputum cultur neg tuberculosi 3 symptom improv andor 4 100 biomark intend predict clinic benefit agenc recommend part phase 2 101 trial design sponsor includ long term follow collect clinic endpoint 102 addit earlier time point 103 104 2 efficaci consider 105 106 investig drug evalu efficaci ad combin gimen 107 alreadi approv drug addit entir new combin regimen compris 108 investig drug evalu efficaci singl adequ well control trial 109 subject pulmonari tb support ed confirmatori evid eg evid 110 antimycobacteri activ nonclin data eba p hase 2 trial may provid evid 111 effect singl trial demonstr clinic meaning statist robust 112 treatment effect 6 see section iii b specif efficaci trial consider 113 discuss regard efficaci consider 114 115 3 safeti consider 116 117 evalu safeti profil investig drug challeng 118 patient pulmonari tb often comorbid condit sponsor evalu potenti 119 drug drug interact may occur c oadministr antimycobacteri 120 drug concom itant medic eg antiretrovir drug 121 6 see draft guidanc industri demonstr substanti evid effect human drug biolog product decemb 2019 final guidanc repres fda current think topic recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document contain nonbind recommend draft implement 4 122 hepatotox qt interv prolong common advers reaction 123 antimycobacteri drug sponsor evalu nvestigat ional drug potenti 124 caus hepatotox qt prolong arrhythm ias7 8 125 126 sponsor discuss size preapprov safeti databas fda drug 127 develop assess risk benefit subject unmet medic need 128 smaller safeti databas approxim 300 subject treat greaterlong 129 propos intend dose durat may suffici safeti signal identi fie larger 130 safeti databas may need 131 132 b specif efficaci trial consider 133 134 1 trial design 135 136 sponsor use follow trial design demonstr superior 137 138 regimen includ one investig drug compar standard 139 regimen efficaci demonstr show superior investig drug 140 regimen standard regimen9 141 142 investig drug plu optim background regimen obr compar 143 match placebo plu obr e fficaci demonstr show 144 superior investig drug regimen placebo contain regimen 145 optim background antimycobacteri treatment base epidemiolog 146 inform vitro suscept test avail 147 148 sponsor use follow trial design demonstr ni 149 150 investig drug regimen compar standard regimen ni would 151 demonstr show investig regimen perform within prespecifi 152 margin perform standard regimen 153 154 investig drug replac one drug st andard combin regimen 155 investig drug regimen perform within accept ni margin 156 base known quantit reliabl contribut drug 157 7 see guidanc f industri drug induc liver injuri premarket clinic evalu juli 2009 8 see ich guidanc industri e14 clinic evalu qtqtc interv prolong pr oarrhythm potenti non antiarrhythm drug octob 2005 e14 clinic evalu qtqtc interv prolong pr oarrhythm potenti non antiarrhythm drug question answer r3 june 2017 s7b nonclin evalu potenti delay ventricular repolar qt interv prolong human pharmaceut octob 2005 m3r2 nonclin safeti studi conduct human clinic trial market author pharmaceut januari 2010 9 see guidanc industri codevelopmen two new investig drug use combin contain nonbind recommend draft implement 5 replac standard regimen ni trial design determin efficaci 158 contribut investig drug regimen 159 160 interpret result ni trial reli justifi ni margin margin 161 highli depend specif design ni trial includ control regimen base 162 part data f rom previous conduct trial evalu histor e videnc ensit 163 drug e ffect hesd estim effect activ control 10 appendix contain 164 exampl n ni margin justif trial 4month regimen drug suscept tb 165 166 fda estim exact numer treatment effect standard regimen 2 167 month treatment ethambutol isoniazid rifampin pyrazinamid follow 4 168 month treatment isoniazid rifampin abbrevi terminolog 2ehrz4hr 169 patient wi th drug suscept pulmonari tb howev consid histor data 170 manag outcom patient pulmonari tb era antibacteri drug 171 therapi highli success result follow treatment 2ehrz4hr support 172 select ni margin base larg degre clinic benefit exampl 173 given success rate 2ehrz4hr exceed 90 percent numer treatment effect 174 like far exceed 10 percent nahid et al 2016 refor base clinic judgement 1 0 175 percent ni margin clinic relev appropri preserv treatment effect 176 ni trial determin efficaci n investig drug regimen whole base 177 comparison 6month standard regimen 178 179 depend new investig drug regimen studi design ni trial potenti impact 180 eg abil fulfil unmet medic need safeti profil regimen may 181 appropri set wider ni margin still plan trial design feasibl provid 182 reason preapprov safeti databas agenc en courag ponsor discuss 183 clinic trial design ni margin justif fda11 184 185 superior trial ni trial assess activ investig drug regimen 186 whole sponsor also need address ad contribut compon 187 regimen 9 may accomplish nonclin trial eba studi phase 2 trial 188 andor part pivot efficaci trial 189 190 2 trial populati 191 192 trial popul includ adult subject appropri pediatr subject 193 pulmonari tb presenc extrapulmonari diseas may requir longer durat 194 treatment pulmonari tb assess endpoint evalu extrapulmonari 195 site trial includ subject either drug suscept drug resist pulmonari tb 196 depend anticip effect antimycobacteri drug evalu 197 198 10 see ich e10 discuss hesd 11 see also articl four month moxifloxacin base regimen drug sensit tuberculosi gillespi et al 2014 contain nonbind recommend draft implement 6 protocol specifi subject handl vitro suscept result 199 avail conduct trial analysi result 200 201 enrich strategi regard trial drug resist tb includ focu contact 202 subject drug resist tb subject area high prevalen ce drug resist 203 subject relap e previou treatment subject diseas progress 204 standard regimen 205 206 3 inclus exclus criteria 207 208 fda r ecommend follow inclus criteria subject pulmonari tb 209 210 presenc afb sputum specimen detect smear microscopi rapid 211 diagnost test microbiolog diagnosi tb confirm cultur 212 least one sputum sampl obtain time enrol 213 214 chest radiograph ic find consist activ pulmonari tb exampl cavitari 215 lesion apic infiltr hilar lymphadenopathi 216 217 minimum two follow sign symptom present least 218 2 week 219 220 sputum product 221 222 cough 223 224 one episod hemoptysi 225 226 fever eg oral temperatur greater equal 380 degre celsiu least 227 two occas 228 229 pleurit chest pain 230 231 weight loss 232 233 night sweat 234 235 use rapid diagnost noncultur test may help identifi subject enrol tb 236 trial test use fda clear sponsor provid suffici inform 237 perform characterist test determin analyt valid studi 238 239 fda r ecommend follow exclus criteria subject pulmonari tb 240 241 one week therapi current episod activ tb unless enrol 242 trial target drug resist tb document lack respons therapi 243 base clinic microbiolog find 244 contain nonbind recommend draft implement 7 245 signif icant concurr ill hiv eg lung cancer may affect outcom 246 assess 247 248 unwil ness compli recommend local public health author 249 manag patient pulmonari tb 250 251 4 random stratif blind 252 253 trial random doubl blind unless sponsor provid scientif 254 adequ explan blind accomplish trial singl blind open 255 label sponsor discuss potenti bias fda bias 256 address trial fulli blind sponsor maintain maximum 257 possibl level blind trial blind assessor blind databas databas 258 lock etc 259 260 sponsor consid tratif subject base certain baselin characterist eg 261 presenc absenc cavitari diseas hiv infect sponsor includ 262 protocol discuss analys account stratifi randomization12 263 264 5 specif popul 265 266 pediatr popul 267 268 fda encourag sponsor begin discuss pediatr clinic develop 269 plan earli feasibl addit safeguard 21 cfr part 50 subpart 270 enrol children cl inic investig affect time design trial support 271 pediatr drug develop accord requir sponsor enrol 272 pediatr subject trial suffici safeti antimycobacteri activ pharmacokineti c pk 273 efficaci data adult subject avail appropri dose regimen pediatr 274 subject characterized13 sponsor includ dolesc subject pulmonari 275 tb phase 3 clinic trial appropriate14 276 277 sponsor must submit pediatr studi plan later 60 calendar day date 278 endofphas 2 meet time agre upon fda sponsor unless 279 12 see draft guidanc industri adjust covari random clinic trial drug biolog product may 2021 final guidanc repres fda current think topic 13 exampl see articl toward earlier inclus children tuberculosi tb drug trial consensu statement expert panel nachman et al 2015 14 see guidanc industri develop anti infect drug product pediatr popul decemb 2021 contain nonbind recommend draft implement 8 investig drug grant orphan designation15 pedi atric formul 280 develop begin soon result adult phase 2b trial known 281 sponsor determin appropri dose regimen 282 283 extrapol adult efficaci treatment pulmonari tb pediatr popul 284 accept pediatr popul except young children 285 differ clinic pathophysiolog characterist sponsor provid pk safeti 286 inform suffici number pediatr subject support appropri dose 287 treatment children pulmonari tb cohort pediatr studi defin base 288 chronolog age weight base criteria particularli oral drug studi drug across 289 pediatr spectrum agesweight conduct parallel rather sequenti 290 unless specif safeti pk properti warrant differ approach existi ng 291 anim studi identifi potenti development concern target organ toxicolog 292 pharmacolog juvenil anim toxic test may appropri 16 17 293 294 pediatr develop plan new tb investig drug could includ children live 295 hiv provid safeti drug drug interact issu manag 296 297 sponsor discuss pediatr develop program fda especi 298 includ young children eg younger 5 year age differ 299 clinic manifest eg increas likelihood extrapulmonari diseas 300 pathophysiolog characterist 301 302 b pregnant femal 303 304 sponsor includ pregnant femal clinic trial femal reproduct toxic 305 studi standard batteri genotox test conduct 18 infant born 306 femal subject receiv investig drug follow investig 307 appropri length time sponsor discuss durat fda trial 308 conduct19 309 15 see section 505b e2a fdc act 21 usc 355 ce2a addit inform see guidanc industri pediatr studi plan content process submit initi pediatr studi plan amend initi pediatr studi plan juli 2020 ich guidanc industri e11 clinic investig medicin product pediatr popul decemb 2000 16 see guidanc industri nonclin safeti evalu pediatr drug product februari 2006 17 support principl 3r reduc refin replac anim use test feasibl encourag sponsor consult review divis consid use nonanim test method believ su itabl adequ valid feasibl consid altern method could assess equival anim test method 18 see draft guidanc industri pregnant women scientif ethic consider inclus clinic trial april 2008 final guidanc repres fda current think topic 19 recommend regard treatment women pregnanc breastfeed see american thorac societi center diseas control prevent infecti diseas societi america guidelin treatment tb nahid et al 2016 avail httpswwwcdcgovmmwrpreview mmwrhtmlrr5211a1htm contain nonbind recommend draft implement 9 310 c spe cific popul 311 312 sponsor includ trial geriatr subjects20 subject renal insuffici diabet 313 mellitu subject hepat impair feasibl high incid tb 314 patient coinfect hiv subject hiv includ trial 315 316 6 dose select 317 318 select dose regimen evalu phase 3 clinic trial sponsor 319 consid target pkpharmacodynam pd paramet eg area curveminimum 320 inhibitori concentr mic maxim concentr mic time mic base 321 vitro model see ection iii c1a vitro studi anim model tb result 322 earli clinic trial eg eba andor trial afb clearanc sputum earli time point 323 result exposur respons evalu pkpd evalu includ evalu 324 base free drug concentr 325 326 7 choic compar 327 328 choic compar background regimen depend part subject popul 329 sponsor enrol trial eg likelihood infect drug suscept drug 330 resist tuberculosi ge neral sponsor choos compar regimen contain 331 fda approv drug repr esent standard care trial initi ponsor 332 discuss fda use compar regimen base local practic outsid 333 unit st ate use drug fda approv 334 335 8 efficaci endpoint 336 337 sponsor use follow efficaci endpoint clinic trial investig drug 338 intend treat pulmonari tb 339 340 primari clinic efficaci endpoint compris surviv evalu 341 tuberculosi growth serial sputum cultur examin fix time point 342 follow random treatment arm includ period follow 343 complet plan treatment period fda defin c linic success 344 failur follow 345 346 clinic success assign subject aliv achiev tuberculosi cultur 347 neg serial sputum examin experi relaps recurr 348 pulmonari tb otherwis meet definit clinic failur gener 349 20 see ich guidanc industri e7 studi support special popul geriatr august 1994 e7 studi support special popul geriatr question answer februari 2012 contain nonbind recommend draft implement 10 protocol defin serial sputum examin occur everi 2 week month 350 treatment everi 3 month follow complet treatment21 351 352 clinic failur defin one follow 353 354 protocol defin clinic progress pulmonari diseas treatment 355 356 switch antimycobacteri therapi toler issu clinic 357 progress pulmonari tb 358 359 sign symptom activ tb includ radiograph worsen compar 360 baselin find result reiniti antimycobacteri thera py 361 follow up22 362 363 death treatment follow 364 365 growth tuberculosi sputum cultur outlin follow 366 367 failur achiev tuberculosi cultur neg serial sputum specimen 368 treatment period 369 370 failur maintain cultur neg statu fter specif time point defin 371 trial gener expect time two consecut neg 372 sputum cultur taken least 28 day apart therapi follow 373 374 growth tuberculosi extrapulmonari site trial 375 376 surrog endpoint base result tuberculosi sputum cultur 377 treatment demonstr treatment effect sputum cultur convers 378 posit neg treatment either time toconvers analysi fix 379 time point eg 2 month random could consid surrog 380 endpoint reason like predict clinic benefit acceler approv 381 statutori regulatori provis 23 addit consider relat acceler 382 approv regard verif descript clinic benefit includ 383 durabl treatment effect discuss section iiib11 acceler approv 384 consider sponsor obtain erial cultur specif time point 385 treatment eg everi 2 week everi month time sputum cultur convers 386 time first steril cultur verifi tuberculosi cultur neg 387 21 protocol defin ed time serial examin sputum cultur may differ clinic practic often depend local treatment guidelin respiratori isol procedur 22 circumst antimycobacteri therapi may restart though diagnost uncertainti whether relaps occur therapi subsequ stop altern diagnosi establish protocol defin durat retreat therapi use defin clinic failur avoid label trial subject situat failur 23 section 506c fdc act 21 cfr 314510 21 cfr 60141 contain nonbind recommend draft implement 11 least two subsequ consecut sputum specimen taken least 14 day apart eg 388 three consecut neg sputum cultur sputum cultur evalu either 389 solid liquid media see section iiib11 acceler approv consider 390 391 secondari exploratori endpoint sponsor consid follow 392 393 well defin reliabl evalu symptom includ 394 clinic trial secondari exploratori endpoint f note symptom evalu 395 certain patient popul may difficult interpret exampl among 396 patient coinfect hiv experi immun reconstitut inflammatori 397 syndrom non hiv infect individu paradox reaction rangaka et al 398 2012 399 400 molecular biochem evalu ascertain whether posit cultur 401 tuberculosi drug treatment repres relaps reinfect eg 402 exploratori endpoint analysi treat relaps baselin tuberculosi 403 infect failur origin studi treatment treat reinfect new 404 tuberculosi isol success origin studi treatment 405 406 9 trial procedur es time assess 407 408 entri visit 409 410 sponsor obtain baselin demograph inform current medic complet 411 physic e xamin entri visit addit sponsor obtain follow 412 entri 413 414 clinic sign symptom pulmonari tb eg cough sputum product episod 415 hemoptysi fever pleurit chest pain weight loss night sweat 416 417 baselin safeti laboratori evalu 418 419 hiv serolog hiv posit viral load cd4 cell count 420 421 imag result standard posterior anterior view later chest radiograph 422 comput ed tomographi scan describ extent sever pulmonari diseas 423 424 sputum specimen afb smear mycobacteri cultur obtain one 425 follow spontan expector nduction hyperton salin bronchoscopi 426 gastric lavag eg pediatr subject applic baselin specimen 427 quantit cultur collect standard manner eg singl earli 428 morn induc sputum pool 24 hour sputum 429 430 contain nonbind recommend draft implement 12 b visit therapi therapi complet 431 432 gener clinic assess occur weekli biweekli first month 433 therapi follow monthli assess therapi complet complet 434 therapi assess occur approxim everi 3 month assess 435 primari efficaci endpoint complet eg 12 month random ass essment 436 sign symptom advers effect laboratori test appropri occur 437 visit addit target physic examin perform 438 439 therapi sponsor obtain putum specimen afb smear cultur least 440 monthli depend investig drug regimen design shorter interv 441 specimen collect eg 2 week may appropri certain period trial 442 443 subject abl expector sputum spontan follow visit therapi 444 complet sponsor consid method obtain sputum eg sputum induct 445 446 10 statist consider 447 448 gener sponsor includ protocol detail statist al analysi plan state 449 trial hypothes efficaci analysi method 450 451 sponsor consid follow definit analysi popul 452 453 safeti popul subject receiv least one dose investig 454 drug trial 455 456 intent totreat itt popul random subject 457 458 microbiolog itt icroitt popul random subject posit 459 cultur tuberculosi pretreat prerandom sampl trial 460 intend focu subject drug resist tb sponsor choos primari 461 analysi micro itt popul random subject posit cultur 462 drug resist isol tuberculosi pretreat prerandom sampl 463 464 perprotocol popul random subject posit cultur 465 pretreat sampl achiev prespecifi level complianc protocol 466 eg presenc high percentag follow visit 467 468 gener analysi popul greatest interest determin efficaci 469 micro itt popul addit sponsor evalu consist result efficaci 470 itt per protocol popul notabl differ outcom 471 itt perprotocol popul sponsor investig reason 472 differ 473 474 subject follow complet durat trial even discontinu 475 investig drug sponsor make everi effort minim loss follow 476 contain nonbind recommend draft implement 13 throughout trial given miss data nonetheless like occur protocol 477 state miss data handl primari efficaci analysi addit ly 478 statist analysi plan defin addit method handl miss data studi 479 report includ n assess depend trial result specif method 480 handl miss data 481 482 improv precis treatment effect estim infer sponsor consid 483 adjust prespecifi baselin factor anticip pro gnostic outcom 484 random stratifi baselin covari analysi account stratifi 485 random 486 487 11 acceler approv consider 488 489 circumst approv 21 cfr part 314 subpart h 21 cfr part 601 subpart 490 e may applic drug develop treatment tb provid clinic 491 meaning benefit exist treatment endpoint base convers sequenti 492 tuberculosi sputum cultur neg eg percent convers prespecifi time 493 point use surrog endpoint reason like predict clinic benefit 494 walli et al 2010 walli et al 2013 phillip et al 2013 walli peppard hermann 2015 495 walli pepp ard 2015 phillip et al 2016 meyvisch et al 2018 sponsor may consid 496 surrog endpoint eg biomark also reason like predict clinic 497 benefit drug approv acceler approv fda requir sponsor 498 studi drug verifi describ clinic benefit24 includ durabl 499 treatment effect sponsor consid sputum cultur convers surrog 500 endpoint reason like predict clinic benefit consult agenc 501 clinic trial plan 502 503 c consider 504 505 1 microbiolog consider 506 507 sponsor nvestig drug evalu treatment tb support 508 data vitro vivo anim model microbiolog studi studi may 509 provid data inform select regimen antimycobacteri drug evalu 510 clinic trial assess contribut drug investig drug regimen 511 512 vitro studi 513 514 vitro studi encompass follow 515 516 investig drug activ inhibit growth kill metabol activ 517 dormant intracellular stage tuberculosi 518 519 24 21 cfr 314510 drug 21 cfr 60141 biolog product contain nonbind recommend draft implement 14 suscept test metabol activ bacilli drug suscept laboratori 520 strain laboratori strain known pattern drug resist clin ical isol 521 repres differ geograph region 522 523 standard method suscept test recommend 524 clinic laboratori standard institut clsi25 525 526 nonstandard method employ trial prior submiss fda review 527 complet descript method perform characterist assay 528 actual laboratori test done 529 530 establish q ualiti control paramet suscept test 531 determin vitro activ 26 532 533 two new investig drug evalu simultan sponsor 534 conduct factori design studi evalu new investig ation drug provid 535 result fda9 fda encourag est multipl strain tuberculosi 536 see section iiic3d vitro hollow fiber system model method assess 537 contribut individu drug combin regimen 538 539 b vivo anim model 540 541 appropri anim model serv import bridg identif 542 vitro antimycobacteri effect investig drug initi clinic trial 543 pk assess chang drug suscept anim model studi may inform clinic 544 trial design sponsor consid evalu investig drug 545 combin investig drug use differ anim mode ls one 546 strainisol tuberculosi studi mycobacteri burden steril activ vivo 547 studi conduct use factori design use clinic relev exposur provid 548 inform contribut individu drug combin regimen 549 550 c drug resist cross resist 551 552 sponsor examin pot ential tuberculosi isol develop resist 553 investig drug appropri vitro andor anim model evalu 554 potenti cross resist drug class class use treatment 555 tb resist demonstr import identifi mechan resist 556 25 exampl ee guidanc industri fda class ii special control guidanc document antimicrobi suscept test ast system august 2009 clsi suscept test mycobacteria nocardia aerob actinomycet approv standard third edit avail httpsclsiorgstandardsproductsmicrobiologydocumentsm24 recent version class ii special control guidanc document check fda class ii special control guidanc document web page httpswwwfdagovmed evicesguid document medic devic andradi emit productsclass iispeci control document 26 detail see guidanc industri microbiolog data system antibacteri drug develop analysi present februari 2018 contain nonbind recommend draft implement 15 sponsor attempt evalu clinic signific chang phenotyp eg 557 vitro suscept investig drug genotyp observ nonclin studi 558 correl chang efficaci outcom 559 560 type cultur media identifi tuberculosi 561 562 solid media eg lwenstein jensen medium middlebrook 7h10 7h11 agar media 563 liquid media eg myco bacteria growth indic tube cultur assay method use 564 identifi character tuberculosi sponsor includ newer molecular 565 methodolog detect tuberculosi suscept profil trial microbiolog 566 evalu sponsor specifi method use cultur identifi tuberculosi 567 well vitro suscept test method employ trial 568 569 baselin evalu agenc recommend use solid liquid media 570 advantag approach 1 rapid observ mycobacteri growth liquid 571 media eg less 2 week 2 growth pure cultur solid media alreadi 572 underway biochem ical confirm tuberculosi b evalu 573 vitro suscept 574 575 evalu subject treatment aft er treatment complet sponsor use 576 solid liquid cultur media within clinic trial cultur meth odolog among trial site 577 consist evalu subject trial type cultur evalu 578 inform secondari exploratori endpoint eg quantit cultur techniqu 579 580 e differenti relaps reinfect new infect 581 582 secondari analysi sponsor aim util mole cular method evalu whether 583 clinic failur caus relaps origin infect develop new 584 infect especi subject live endem area method use 585 clinic trial sponsor shoul includ detail method use well perform 586 characterist assay clinic protocol 587 588 2 relev nonclin safeti consider 589 590 combin regimen remain standard care treatment tb individu drug 591 may develop treatment activ diseas although would use part 592 combin regimen nonclin studi character safeti profil individu drug 593 combin regimen support clinic trial approv market applic 594 vari depend inform avail drug intend patient 595 population27 agenc encourag sponsor discuss fda avail toxicolog 596 27 guidanc conduct nonclin combin studi support clinic trial combin regimen see follow 1 guidanc industri nonclin safeti evalu drug biolog combin march 2006 2 ich guidanc industri m3r2 nonclin safeti studi conduct human clinic trial market author pharmaceut 3 ich guidanc industri s6r1 preclin safeti evalu biotechnolog deriv pharmaceut may 2012 4 guidanc industri codevelop two new investig drug use combin contain nonbind recommend draft implement 16 data investig drug propos clinic develop combin 597 regimen 598 599 sponsor conduct nonclin toxicolog studi combin regimen consist 600 two investig unapprov drug initi administr combin 601 regimen human base follow 602 603 avail clinic experi individu drug 604 605 avail relev nonclin toxicolog data individu drug 606 propos durat combin regi men 607 608 exist signific toxicolog concern safeti margin 609 observ advers effect level noael individu drug anim 610 toxicolog studi propos human exposur investig drug 611 combin regimen 612 613 potenti drug drug interact base absorpt distribut 614 metabol excret drug 615 616 potenti advers effect involv organ system overlap 617 toxic synergist toxic base review accumul data 618 investig drug 619 620 sponsor discuss fda type durat time nonclin toxicolog 621 studi need support clinic developm nt combin regimen 622 623 3 pkpd consider 624 625 phase 1 phase 2 pk trial 626 627 pk investig drug fulli character singl dose pk multipl 628 dose pk phase 2 pkpd evalu fda recommend character pk 629 specif popul includ subject renal hepat impair well 630 evalu drug effect qt interv 28 631 632 b drug interact 633 634 sponsor conduct n vitro studi determin pote ntial investig drug 635 act substrat inhibitor induc major human metabol enzym relev 636 transport 29 base result drug interact evalu one 637 28 see ich guidanc ind ustri e14 clinic evalu qtqtc interv prolong proarrhythm potenti non antiarrhythm drug question answer r1 octob 2012 29 see guidanc industri vitro drug interact studi cytochrom p450 enzym transport mediat drug interact januari 2020 contain nonbind recommend draft implement 17 antimycobacteri drug use plan combin regimen drug unrel 638 treatment tb like use concomitantli indic eg antiretrovir 639 therapi treatment hiv antivir therapi treatment hepat b c may need 640 initi clinic efficaci trials30 agenc strongli recommend sponsor 641 consult fda drug develop regard appropri drug interact evalu 642 643 c exposur respons 644 645 sponsor explor e xposur respons relationship earli phase drug 646 develop aid select optim dose strategi evalu later trials31 647 fda encourag sponsor explor exposur respons relationship sputum 648 serum drug concentr marker activ eg time tosputum convers 649 sputum convers rate 2 month subject pulmonari tb 650 651 vitro hollow fiber system model 652 653 sult hollow fiber system model combin sourc nonclin data 654 help inform select antimycobacteri drug regimen begin clinic evalu 655 chilukuri et al 2015 hollow fiber system model use si mulat pk 656 characterist drug intend treat tb allow explor concentr 657 effect relationship potenti relev treatment tb clinic set hese 658 model expect provid key inform regim en select evalu 659 model may also play import role evalu contribut drug 660 clinic relev exposur treatment effect 661 662 4 foreign clinic data32 663 664 fda regul permit accept foreign clinic trial support new drug 665 applic nda biolog licens applic bla approv 21 cfr 312120 666 667 5 data standard tb 668 669 studi data standard describ standard ize way exchang clinic nonclin research 670 data comput system data standard develop tb provid 671 30 see guidanc industri clinic drug interact studi cytochrom p450 enzym transport mediat drug interact januari 2020 31 see guidanc industri exposur respons relationship studi design data analysi regulatori applic april 2003 32 see guidanc industri fda staff fda accept foreign clinic studi conduct ind fr equent ask question march 2012 contain nonbind recommend draft implement 18 consist gener framework organ studi data includ templat dataset 672 standard name variabl standard way calcul common variables33 673 674 6 label consider 675 676 gener label indic reflect patient popul enrol clinic 677 trial exampl sponsor consid follow 678 679 drug x indic combin drug z treatment pulmonari 680 tuberculosi 681 682 683 684 drug x indic combin antimycobacteri drug treatment 685 pulmonari tuberculosi 686 687 drug approv acceler approv sponsor must includ addit inform 688 indic usag section see 21 cfr 20157c2ib 34 drug 689 approv l imit popul pathway ntibacteri antifung drug addit 690 inform avail specif label requir recommendations35 36691 33 see exampl tb therapeut area user guid version 2 avail httpswwwcdiscorgstandardstherapeut areastuberculosistuberculosi therapeut areauserguid v20 fda studi data standard resourc web page avail httpswwwfdagovforindustrydatastandardsstudydatastandardsdefaulthtm 34 see guidanc industri expedit program seriou condit drug biolog 35 see section 506h3a fdc act amend 21st centuri cure act 36 see guidanc industri limit popul pathway antibacteri antifung drug august 2020 contain nonbind recommend draft implement 19 refer 692 693 bark cm r dietz okwera et al 2011 clinic symptom mi crobiolog outcom 694 tuberculosi treatment trial tuberculosi 916 601604 695 696 chilukuri mcmaster k bergman et al 2015 hollow fiber system model 697 nonclin evalu antituberculosi drug regimen clin infect di 61 su ppl 698 1s32s33 699 700 dersimonian r n laird 1986 meta analysi clinic trial control clin trial 701 73177188 702 703 east african british medic research council 1981 control c linic trial f ive hort 704 cours 4 month c hemotherapi regimen pulmonari tuberculosi rev respir di 705 1232 165 170 706 707 east central africabritish medic research council fifth collabor studi 1983 708 control clinic rial 4 hortcours r egimen c hemotherapi three 6 month 709 one 8 month p ulmonari uberculosi tubercl 643153 166 710 711 gillespi sh crook td mchugh et al 2014 four month moxifloxacin base regimen 712 drug sensit tuberculosi new engl j med 37117 1577 1587 713 714 johnson jl dj hadad r dietz et al 2009 shorten reatment adult w ith noncavitari 715 tuberculosi 2 month cultur convers j respir crit care med 1806 558 563 716 717 makuch rw rm simon 1980 sampl size consider non random 718 compar studi j chron di 333 175181 719 720 meyvisch p c kambili k andri et al 2018 evalu six month sputum cultur 721 convers surrog endpoint multidrug resist tuberculosi trial plo one 722 137e0200539 723 724 nachman ahm f amanullah et al 2015 toward earlier inclus children 725 tuberculosi tb drug trial consensu statement expert panel lancet infect di 726 156711720 727 728 nahid p se dorman n alipanah et al 2016 offici american thorac societycent 729 diseas control preventioninfecti diseas societi america clinic practic 730 guidelin treatment drug suscept tuberculosi clin infect di 637853 867 731 732 nunn aj pp j phillip sh gillespi 2008 design issu pivot drug trial drug 733 sensit tuberculosi tb tuberculosi 88suppl 1s85 s92 734 735 perez velez cm bj marai 2012 tuberculosi children new engl j med 3674 348 736 361 737 contain nonbind recommend draft implement 20 phillip ppj cm mendel da burger crook aj nunn r dawson et al 2016 limit 738 role c ultur c onvers ecis make ndividu p atient c dvanc 739 novel r egimen c onfirmatori c linic rial bmc med 1419 740 741 phillip ppj k field aj nunn 2013 e valuat c ultur r esult ure 742 treatment tuberculosi urrog e ndpoint reatment f ailur r elaps plo 743 one 85 e63840 744 745 rangaka mx rj wilkinson jr glynn et al 2012 effect antiretrovir therapi 746 diagnost accuraci symptom screen intensifi tuberculosi case find 747 south african hiv clinic clin infect di 5512 16981706 748 749 singapor tuberculosi servicebritish medic research council 1986 long term follow 750 c linica l trial ixmonth fourmonth r egimen c hemotherapi reatment 751 pulmonari uberculosi rev respir di 1335779 783 752 753 walli rs peppard 2015 earli b iomark r egulatori nnovat multidrug 754 resist uberculosi clin infect di 61 suppl 3 s160 s163 755 756 walli rs c wang tm doherti p onyebujoh vahedi h laang et al 2010 biomark 757 uberculosi iseas ctiviti c ure r elaps lancet infect di 102 6869 758 759 walli rs c wang meyer n thoma 2013 month 2 c ultur statu reatment 760 durat predictor uberculosi r elaps r isk etaregress odel plo one 761 88 e71116 762 763 walli rs peppard hermann 2015 month 2 c ultur tatu reatment durat 764 predictor r ecurr p ulmonari uberculosi odel v alid u pdate plo 765 one 104 e0125403 766 767 wejs c p gustafson j nielson et al 2008 tbscore sign symptom tuberculosi 768 patient low resourc set predict valu may use assess clinic 769 cours scand j infect di 402 111120 770 contain nonbind recommend draft implement 21 appendix 771 exampl justif noni nferior margin 772 treatment shorten clinic trial pulmonari tuberculosi 773 774 appendix provid exampl noninferior ni margin justif state 775 guidanc ni margin justif depend specif design ni trial 776 justif specif ni trial w ould compar n investig drug regimen 777 consist new investig drug plu first 4 month standard regimen 778 standard 6month regimen subject drug suscept tuberculosi tb effect 779 investig drug essenti replac effect month 5 6 standard regimen 780 use histor data justif determin effect 2 month therapi 781 histor evid sensit drug e ffect hesd de termin new 782 investig drug effect base result ni trial addit inform 783 avail regard complet discuss ni trial justif margin 1 784 785 identifi two trial allow esti mate effect onth 5 6 786 standard regimen drug suscept tb base comparison standardof care 787 regimen 2 month treatment ethambutol streptomycin isoniazid rifampin 788 pyrazinamid follow 4 month treatment isoniazid rifampin often 789 describ abbrevi terminolog 2ehrz4hr 2shrz4hr 4 month regimen 790 2ehrz2hr 2shrz2hr 2 endpoint unfavor outcom defin one 791 follow 1 subject never becom sputum cultur neg tuberculosi 792 therapi 2 subject microbiolog confirm relaps pulmonari tb within 793 12month period observ follow therapi complet 3 subject die 794 time within clinic trial drug administr period 12month period observ 795 follow therapi complet 796 797 tabl contain result two trial among subject random receiv 798 6 month regimen 4 month regimen comparison two regimen give 799 estim effect final 2 month 6 month regimen 84 percent lower 800 bound 95 percent confid interv 48 percent 48 percent use 801 conserv estim treatment effect month 5 6 treatment 802 803 1 see guidanc industri noninferior clinic trial establish effect novemb 2016 updat guidanc period make sure recent version guidanc check fda guidanc web page httpswwwfdagovregulatori informationsearch fdaguid document 2 see singapor tuberculosi servicebritish medic research council 1986 east central africabritish medic research council fifth collabor studi 1983 east africanbritish medic research council 1981 contain nonbind recommend draft implement 22 tabl result wo treatment shorten tudi 804 805 studi 6month regimen unfavor outcom 4month regimen unfavor outcom treatment effect 4 month regimen minu 6 month regimen 95 ci 1 2shrz4hrz 12 2158 2shrz2hrz 96 15156 84 38 142 2 2shrz4hr 47 8172 2shrz2hrz 132 28212 86 24 146 summari estim 95 ci 84 48 121 ci confid interv 2shrz4h rz 2 month treatment streptomycin isoniazid rifampin 806 pyrazinamid follow 4 month treatment isoniazid rifampin pyrazinamid 2shrz2hrz 807 2 month treatment streptomycin isoniazid rifampin pyrazinamid follow 2 month treatment 808 isoniazid rifampin pyrazinamid 809 number death unknown studi 1 therefor includ outcom 6 month 4 810 month regimen studi 2 separ trial howev similarli design conduct 811 occur close time studi 1 singapor tuberculosi servicebritish medic research council 1986 long 812 term follow clinic trial six month four month regimen chemotherapi treatment 813 pulmonari tuberculosi rev respir di 1335779 783 studi 2 east central africabritish medic 814 research council fifth collabor studi 1983 control clinic trial 4 hort cours regimen 815 chemotherapi three 6 month one 8month pulmonari tuberculosi tubercl 643153 166 east 816 africanbritish medic research council 1981 control clinic trial five short cours 4 month 817 chemotherapi regimen pulmonari tuberculosi rev respir di 1232165 170 818 random effect model per dersimonian r n laird 1986 meta analysi clinic trial control clin 819 trial 73177 188 820 821 ni trial subject drug suscept pulmonari tb tr eatment shorten 822 regimen compar standard 6month regimen select n ni margin 48 percent 823 support histor data ni margin justif present 824 modif justif present nunn et al 2008 3 825 826 although ni margin 48 percent may seem ly conserv fact high 827 proport subject achiev success primari efficaci outcom standard care 828 provid reason estim f sampl size ni trial addit given high 829 proport subject achiev success outcom interest maintain high 830 proport new investig drug regimen exampl identifi trial johnson et 831 al 20094 describ halt trial data monitor committe base 832 approxim 5 percentag point estim differ standard regimen 833 treatment shorten regimen indic clinic expecta tion 834 high proport subject achiev success outcom treatment group make 835 select n ni margin 48 percent feasibl consider 836 837 3 nunn aj ppj phillip sh gillespi 2008 design issu pivot drug trial drug sensit tuberculosi tb tuberculosi 88suppl 1s85 s92 4 johnson jl dj hadad r dietz et al 2009 shorten treatment adult noncavitari tuberc ulosi 2month cultur convers j respir crit care med 1806558 563 contain nonbind recommend draft implement 23 follow exampl provid framework discu sion fda sampl size 838 estim ni trial evalu treatment shorten regimen makuch simon 1980 5 839 total sampl size enrol subject approxim 480 subject per arm base 840 follow ing assumpt 1 identif mycobacterium tuberculosi 90 percent 841 enrol subject primari analysi popul approxim 430 subject per arm 2 two 842 side type error 005 power 90 percent 3 arm rate 5 percent 843 subject endpoint failur convert neg sputum cultur 844 experi relaps tb death 12 month period observ 4 ni margin 845 48 percent 846 847 sponsor discuss fda appropri ni margin specif ni trial 848 propos 849 5 makuch rw rm simon 1980 sampl size consider non random compar studi j chron di 333175 181